{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06500429",
            "orgStudyIdInfo": {
                "id": "NG101-202"
            },
            "organization": {
                "fullName": "Neurogastrx, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist",
            "officialTitle": "A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist",
            "therapeuticArea": [
                "Endocrinology",
                "Other"
            ],
            "study": "a-study-to-evaluate-the-safety-and-efficacy-of-in-adult-participants-receiving-a-glp-agonist"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-18",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-08",
            "studyFirstSubmitQcDate": "2024-07-12",
            "studyFirstPostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Neurogastrx, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period.\n\nThe goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a GLP-1 agonist, in the management of gastrointestinal side effects commonly associated with GLP-1 agonists for overweight or obesity. Adverse event information will be collected. GI-specific questionnaires will be used to capture additional details if GI-related adverse events are reported."
        },
        "conditionsModule": {
            "conditions": [
                "Overweight and Obesity",
                "Healthy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NG101 20 mg BID",
                    "type": "EXPERIMENTAL",
                    "description": "NG101 (metopimazine mesylate) 20 mg capsule BID + single SC dose of 0.5 or 1 mg semaglutide",
                    "interventionNames": [
                        "Drug: NG101",
                        "Drug: Semaglutide Injectable Product"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo capsule BID + single SC dose of 0.5 or 1 mg semaglutide",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Semaglutide Injectable Product"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NG101",
                    "description": "Drug: Including placebo",
                    "armGroupLabels": [
                        "NG101 20 mg BID"
                    ],
                    "otherNames": [
                        "metopimazine mesylate"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Drug: Including placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Semaglutide Injectable Product",
                    "description": "Semaglutide 0.5 or 1 mg",
                    "armGroupLabels": [
                        "NG101 20 mg BID",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Duration of GI-related adverse events",
                    "description": "Number of days with TEAEs of GI-related adverse events following GLP-1 agonist injection",
                    "timeFrame": "96 hours following GLP-1 agonist injection"
                },
                {
                    "measure": "Severity of GI-related adverse events",
                    "description": "Moderate and/or severe TEAES of GI-related adverse events following GLP-1 agonist injection",
                    "timeFrame": "96 hours following GLP-1 agonist injection"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of TEAEs of GI-related adverse events",
                    "description": "Number of TEAEs of GI-related adverse events following GLP-1 agonist injection",
                    "timeFrame": "96 hours following GLP-1 agonist injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy adult\n* Male or female\n* BMI between 22 - 35 kg/m2 at screening\n\nExclusion Criteria:\n\n* Presence or history of illness that might confound the results of the study or pose an -\n* History of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen\n* History or presence of Type 1 or Type 2 diabetes",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Neurogastrx, Inc. (Sponsor)",
                    "role": "CONTACT",
                    "phone": "781-730-4040",
                    "email": "info@neurogastrx.com"
                },
                {
                    "name": "Kimberley Cummings",
                    "role": "CONTACT",
                    "email": "kcummings@neurogastrx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Celerion",
                    "status": "RECRUITING",
                    "city": "Tempe",
                    "state": "Arizona",
                    "zip": "85283",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carol Livingston",
                            "role": "CONTACT",
                            "phone": "602-437-0097",
                            "email": "carol.livingston@celerion.com"
                        },
                        {
                            "name": "Hannah Malashock, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.41477,
                        "lon": -111.90931
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "asFound": "Overweight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000591245",
                    "term": "Semaglutide"
                },
                {
                    "id": "C000005260",
                    "term": "Metopimazine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000097789",
                    "term": "Glucagon-Like Peptide-1 Receptor Agonists"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9043",
                    "name": "Glucagon",
                    "relevance": "LOW"
                },
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M353561",
                    "name": "Semaglutide",
                    "asFound": "Stretching",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227506",
                    "name": "Metopimazine",
                    "asFound": "BMS-931699",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3401",
                    "name": "Glucagon-Like Peptide-1 Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                }
            ]
        }
    },
    "hasResults": false
}